Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444245 (THOR-707) + cemiplimab in advanced skin cancers
NCT04913220Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jul 2021
- Primary completion
- Aug 2023
- Modality
- Cytokines & Interferons
- Countries
- 7
01
Overview
Phase 2, open-label trial of pegenzileukin in melanoma and cutaneous squamous cell carcinoma (cSCC) (2 cohorts), sponsored by Sanofi. Primary endpoint: Objective Response Rate at 25 months. Started Jul 2021; status: terminated.
02
Drugs
pegenzileukin
03
Conditions
melanomacutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04913220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913220.